Forte Biosciences (FBRX) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
4 analysts covering Forte Biosciences (FBRX) carry an average price target of $73.00 as of November 2026, -5.2% against the $76.99 share price on August 26, 2026. The published targets run from $61.00 to $77.00, a spread of 22% of the average, so the disagreement is narrow. The rating split is 1 buy, 3 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.
FBRX analyst price targets
FBRX analyst data as of November 2026, sourced from Yahoo Finance and may be delayed. The price is the last one Yahoo Finance reported on August 26, 2026.A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.
The average target of $73.00 sits roughly in line with the $76.99 price, -5.2%. The median is $77.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.
What the FBRX target range actually tells you
The published targets span $61.00 to $77.00. That gap is 22% of the average target, which counts as narrow disagreement. A spread that tight means the analysts broadly agree on the model, so the consensus is a reasonably stable read of a shared view.
The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the FBRX is it a buy page.
Recent analyst actions on FBRX
| Firm | Action | Target | Prior | Date |
|---|---|---|---|---|
| Barclays | Raised (Equal-Weight) | $77.00 | $74.00 | July 28, 2026 |
| Barclays | Initiated (Overweight) | $74.00 | - | July 21, 2026 |
The most recent published rating actions on FBRX within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.
In the last six months there has been 1 raise and 0 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving. Note the tension here: the average target sits below the current price, yet the recent individual actions have mostly been raises. That usually means the published average has not caught up with the most recent revisions, and it is a good reason not to lean on the average alone.
How analysts rate FBRX
Of the analysts with a published rating, 1 say buy, 3 say hold, and 0 say sell, so 25% carry a buy. That buy share has fallen over the last three months, so sentiment is drifting more negative.
The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.
Why a FBRX price target is not a prediction
- It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
- The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
- Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
- Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.
FBRX earnings and revenue forecast
For the fiscal year ending Dec 2026, the one analyst publishing estimates on FBRX expects earnings of -$4.48 per share.
| Period | EPS estimate | EPS growth | Revenue estimate | Revenue growth |
|---|---|---|---|---|
Quarter ending Sep 2026 next quarter to report, 1 analyst | -$1.09 | n/a | - | - |
Quarter ending Dec 2026 the quarter after, 1 analyst | -$1.11 | n/a | - | - |
Fiscal year ending Dec 2026 fiscal year next to report, 1 analyst | -$4.48 | n/a | - | - |
Fiscal year ending Dec 2027 the fiscal year after, 4 analysts | -$4.08 -$5.91 to -$2.89 | n/a | - | - |
Consensus estimates for FBRX published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.
Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Forte Biosciences next reports around November 9, 2026 (an estimated date), which is when these figures get tested against actual results.
Is there a 2030 forecast for FBRX?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering FBRX do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Forte Biosciences can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move FBRX from here
In short: the drivers cited most often are The argenx acquisition, FB102 platform breadth, Clinical catalysts that drove the price. The risk cited most often against it is for former FBRX shareholders, the operating risks that once defined the stock (single-asset trial failure, cash burn, dilution, and competition) no longer apply to them, because the merger converted their shares into a fixed $77.00 cash payment.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the FBRX is it a buy page.
Your questions about Forte Biosciences
Ask Walnut's AI anything about FBRX and see how it fits what you own.
FAQ
What is the price target for Forte Biosciences (FBRX)?
+
The average analyst price target for FBRX is $73.00 as of November 2026, across 4 analysts. The average is -5.2% against the $76.99 share price on August 26, 2026, so the consensus sits roughly in line with where the stock trades. The median target, which is less distorted by one extreme view, is $77.00. Targets move constantly; verify the current figure before relying on it.
How high could FBRX go?
+
The highest published target is $77.00, which is +0.0% against the $76.99 price. It is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $61.00. The gap between them answers this question best: analysts who all follow Forte Biosciences closely disagree by 22% of the average target, so treat any single number as one scenario.
How many analysts cover FBRX?
+
4 analysts publish estimates on FBRX as of November 2026. Of those with a published rating, 1 say buy, 3 hold, and 0 sell, so 25% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.
Are analyst price targets for FBRX accurate?
+
Treat them as informed opinion, not measurement. Two things matter here. Sell-side ratings skew positive across the market, and FBRX is no exception at 25% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.
Has the FBRX price target been raised or cut recently?
+
In the last six months there has been 1 raise and 0 cuts among the published actions on FBRX. The most recent was Barclays, which raised its target to $77.00 from $74.00 on July 28, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.
Is analyst sentiment on FBRX improving?
+
Over the last three months the share of analysts rating FBRX a buy has been falling. The shift is in opinion, not in the business, and it often lags the news that caused it. It is best read alongside the target revisions.
What are analysts' earnings estimates for Forte Biosciences (FBRX)?
+
For the fiscal year ending Dec 2026, the one analyst publishing estimates on FBRX expects earnings of -$4.48 per share. For the fiscal year ending Dec 2027, the consensus is -$4.08 per share. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.
When does FBRX report earnings next?
+
Forte Biosciences's next earnings report is expected around November 9, 2026, a date estimated from its reporting history that the company has not yet confirmed. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.
What is the FBRX stock price prediction for 2030?
+
There is no published one. Analyst targets run to about twelve months and no firm covering FBRX publishes a 2030 figure, so any site showing one has extrapolated a growth rate of its own. The answerable version of the question is what the current price already assumes about Forte Biosciences's earnings, which the forward multiple on this page sets out, and what would have to change for that to break.
Will FBRX go up in 2026?
+
Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is useful and different from a prediction. The risk most often cited against Forte Biosciences: For former FBRX shareholders, the operating risks that once defined the stock (single-asset trial failure, cash burn, dilution, and competition) no longer apply to them, because the merger converted their shares into a fixed $77.00 cash payment. Walnut is not an investment adviser.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on August 26, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.